Abstract
INTRODUCTION AND OBJECTIVE:
Patient-Reported Outcome Measures (PROMs) represent important endpoints in metastatic prostate cancer (mPCa) and in the assessment of Quality of Life (QoL). However, the accurate measurement of health-related quality of life depends on the psychometric properties of the PROMs considered. We aimed to appraise, compare, and summarize the properties of PROMs used in mPCa.
METHODS:
Within the framework of the work package 2 of PIONEER an IMI2 European network of excellence for big data in PCa, we assessed the psychometric properties of PROMs used in Randomized Controlled Trials (RCTs) including patients with mPCa. All available PROMs were identified through a systematic review of the literature performed on Medline in September 2021. All identified PROMs were systematically evaluated according to the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) criteria by two independent Reviewers.
RESULTS:
Our systematic review identified only seven PROMs utilized in RCTs which focused on patients with mPCa. The most frequently used PROMs in RCTs of patients with mPCa were Functional Assessment for Cancer Therapy-Prostate (FACT-P) (n=18), Brief Pain Inventory-Short Form (BPI-SF) (n=8) and European Organization for Research and Treatment of Cancer quality of life core 30 (EORTC QLQ-C30) (n=6). A total of 283 abstracts were screened and 12 full-text studies were evaluated. A total of 2, 1, and 2 studies reported the psychometric proprieties of FACT-P, Brief Pain Inventory (BPI) and BPI-SF. FACT-P and BPI showed a high Content Validity, while BPI-SF showed a moderate Content Validity. FACT-P and BPI showed a high Internal Consistency (summarized Cronbach’s α 0.70-0.95).
CONCLUSIONS:
The use of BPI and FACT-P in mPCa patients is supported by their high content validity and internal consistency. Since BPI is focused on pain assessment, we recommend FACT-P, which provides a broader assessment of QoL and wellbeing, for the clinical evaluation of mPCa patients. However, these considerations have been elaborated on a very limited number of studies.
Patient-Reported Outcome Measures (PROMs) represent important endpoints in metastatic prostate cancer (mPCa) and in the assessment of Quality of Life (QoL). However, the accurate measurement of health-related quality of life depends on the psychometric properties of the PROMs considered. We aimed to appraise, compare, and summarize the properties of PROMs used in mPCa.
METHODS:
Within the framework of the work package 2 of PIONEER an IMI2 European network of excellence for big data in PCa, we assessed the psychometric properties of PROMs used in Randomized Controlled Trials (RCTs) including patients with mPCa. All available PROMs were identified through a systematic review of the literature performed on Medline in September 2021. All identified PROMs were systematically evaluated according to the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) criteria by two independent Reviewers.
RESULTS:
Our systematic review identified only seven PROMs utilized in RCTs which focused on patients with mPCa. The most frequently used PROMs in RCTs of patients with mPCa were Functional Assessment for Cancer Therapy-Prostate (FACT-P) (n=18), Brief Pain Inventory-Short Form (BPI-SF) (n=8) and European Organization for Research and Treatment of Cancer quality of life core 30 (EORTC QLQ-C30) (n=6). A total of 283 abstracts were screened and 12 full-text studies were evaluated. A total of 2, 1, and 2 studies reported the psychometric proprieties of FACT-P, Brief Pain Inventory (BPI) and BPI-SF. FACT-P and BPI showed a high Content Validity, while BPI-SF showed a moderate Content Validity. FACT-P and BPI showed a high Internal Consistency (summarized Cronbach’s α 0.70-0.95).
CONCLUSIONS:
The use of BPI and FACT-P in mPCa patients is supported by their high content validity and internal consistency. Since BPI is focused on pain assessment, we recommend FACT-P, which provides a broader assessment of QoL and wellbeing, for the clinical evaluation of mPCa patients. However, these considerations have been elaborated on a very limited number of studies.
| Original language | English |
|---|---|
| Pages (from-to) | e491 |
| Number of pages | 1 |
| Journal | Journal of Urology |
| Volume | 209 |
| Issue number | Supplement 4 |
| DOIs | |
| Publication status | Published - Apr 2023 |
| Event | AUA 2023 - Chicago, United States Duration: 28 Apr 2023 → 1 May 2023 https://www.auanet.org/AUA2023 |
